Arecor has been given the green light from Austrian regulators to begin a Phase I trial of its AT247 Type I diabetes treatment.
The Austrian Federal Office for Safety in Health Car (BASG) has approved Arecor’s Phase I clinical trial application (CTA).
“We are pleased that the CTA has been approved to enable a clinical study of AT247,” said chief executive Sarah Howell.
“We believe that this product candidate meets a recognised need to develop faster-acting insulins to further improve the lives of people managing Type I diabetes.”
She added; “This is an important milestone for Arecor and we look forward to providing further updates as AT247 progresses through clinical development.”
AT247 is an injection designed to speed up the absorption of glucose after eating and generates a physiological response more like that of a healthy person.
The study will compare the drug’s pharmacokinetic and pharmacodynamic profiles with two current best in class products - Novo Nordisk’s Novolog and Fiasp. It will also assess the safety and efficacy aspects.